跳至主要内容
临床试验/NCT05311423
NCT05311423Unknown不适用

The Prevalence of Genital Tuberculosis and the Impact on Reproductive Outcomes in Infertile Women: a National Multicenter Prospective Cohort Study

Huashan Hospital1 个研究点 分布在 1 个国家目标入组 3,000 人开始时间: 2021年12月1日最近更新:
适应症

试验速览

阶段
不适用
入组人数
3,000
试验地点
1
主要终点
Clinical pregnancy rate of ART

研究概览

简要总结

Female genital tuberculosis infection (FGTB) is an important cause of female infertility in TB-endemic areas. The pregnancy rate of assisted reproductive treatment (ART) in the infertile women with FGTB is still unsatisfied even after receiving standard anti-tuberculosis treatment. Moreover, recent years have witnessed an alarming increase in reports of FGTB-related maternal and neonatal complications after fertility treatments. These underscore that timely detection and treatment of FGTB before ART hold benefit for the mother and child.

详细描述

This project aims to recruit infertile female with high risk of tuberculosis infecton who need assisted reproductive treatment in multiple reproductive centers. The infertility-related medical history and laboratory examination results were recorded according to clinical routine, and other essential information such as tuberculosis symptoms, tuberculosis-related history and other health conditions were also recorded, and the pregnancy outcomes of these patients were followed up.

According to the results of clinical screening, they were divided into four cohorts: non-tuberculosis (non-TB) group, latent tuberculosis infection (LTBI) group, subclinical genital tuberculosis infection (SGTB) group and female genital tuberculosis infection (FGTB) group.

Non-TB group: QuantiFERON-TB test (QFT) negative, continue assisted reproductive treatment; LTBI group: QFT positive. Excluded active pulmonary tuberculosis, patients have negative endometrial histopathology, acid-fast bacilli (AFB) microscopy, Mycobacterium tuberculosis (Mtb) culture, or GeneXpert MTB/RIF Ultra test results. Then assisted reproductive treatment can be continued, but follow-up for tuberculosis-related symptoms is required; SGTB group: QFT positive. Excluded active pulmonary tuberculosis, patients have negative endometrial histopathology, AFB microscopy, Mtb culture, but GeneXpert MTB/RIF Ultra positive test results. They are recommended to receive 6-month first-line standard anti-tuberculosis treatment (ATT) regimen; FGTB group: QFT positive. Excluded active pulmonary tuberculosis, regardless of GeneXpert MTB/RIF Ultra results, at least one of these test results, including endometrial histopathologiy, AFB microscopy, Mtb culture is positive, they will receive 6-month ATT.

Patients diagnosed with SGTB and FGTB will receive 6-month first-line standard ATT before ART, and follow up their anti-tuberculosis drug-related adverse reactions (TB-ARs) according to clinical routine to prevent the occurrence of grade 3-4 adverse drug reactions.

All cohorts will be followed up for pregnancy outcomes after entering the assisted reproduction cycle, and the pregnancy outcomes of all subjects after the first assisted reproduction after enrollment were recorded. Follow-up nodes included the 2nd, 4th, 10th weeks and 37th weeks of gestation. Follow-up content includes pregnancy status. Follow-up subjects will be terminated when adverse pregnancy outcomes such as ectopic pregnancy and miscarriage occurred; follow-up of pregnant participants will be extended to 2 weeks postpartum. Participants from the SGTB or FGTB group achieve pregnant naturally after drug withdrawal, the follow-up of the natural pregnancy outcome will be started as well.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
20 Years 至 43 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Female, aged ≥20 years and <43 years old;
  • In line with conventional assisted reproduction indications;
  • Meet any of the following:
  • with tuberculosis infection history;
  • with a history of close contact to tuberculosis patients;
  • exact positive IGRA results in the past or chest imaging indicated a past history of pulmonary tuberculosis;
  • suspected symptoms of tuberculosis, including fever, night sweats, fatigue, cough and sputum;
  • suspected symptoms of genital tuberculosis, including lower abdominal pain, abnormal menstruation, fallopian tube stenosis, obstruction, thickening, beading changes, uterine cavity adhesions, deformation, pelvic adhesions, etc.;
  • Voluntarily join the study and sign the informed consent

排除标准

  • Co-infection with HIV;
  • Chromosomal abnormalities;
  • suspected genital tuberculosis infection symptoms (participants meet inclusion criteria 3)e in Inclusion Criteria) known to be caused only by factors part from tuberculosis, such as endocrine factors, history of ectopic pregnancy, history of uterine curettage, chronic pelvic inflammatory disease, endometriosis, malignant tumors, etc.;
  • There are other serious physical or mental illnesses that are not suitable for selection;
  • Participate in other clinical studies that would affect this study at the same time.

结局指标

主要结局

Clinical pregnancy rate of ART

时间窗: 2 years

the number of participants with gestational sacs seen by ultrasound examination 4-6 weeks after transplantation/the number of embryo transfer cycles in this group

Prevalence of SGTB among infertile women

时间窗: 6 months

the number of SGTB participants/the total number of this project

Continued pregnancy rate of ART

时间窗: 2 years

the number of patients whose pregnancy was confirmed by repeat ultrasonography at 10th week of gestation/the number of embryo transfer cycles in this group

次要结局

  • Prevalence of FGTB/LTBI among infertile women(2 years)
  • Preterm birth rate(2 years)
  • Neonatal mortality rate(2 years)
  • Spontaneous pregnancy rate(2 years)
  • The rate of drug discontinuation due to adverse drug reactions(2 years)
  • Abortion rate(2 years)
  • Ectopic pregnancy rate(2 years)
  • Live birth rate(2 years)
  • Maternal mortality rate(2 years)
  • The incidence of grade 3-4 adverse events(2 years)
  • Treatment completion rate(2 years)
  • Incidence of active tuberculosis of LTBI group during 1 year after enrollment(1 year)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Wen-hong Zhang

director of department of infectious diseases

Huashan Hospital

研究点 (1)

Loading locations...

相似试验